Edition:
United States

Endocyte Inc (ECYT.OQ)

ECYT.OQ on NASDAQ Stock Exchange Global Select Market

17.33USD
20 Jul 2018
Change (% chg)

$0.23 (+1.35%)
Prev Close
$17.10
Open
$17.16
Day's High
$17.66
Day's Low
$17.10
Volume
228,521
Avg. Vol
474,494
52-wk High
$17.69
52-wk Low
$1.17

Chart for

About

Endocyte Inc. (Endocyte) is a biopharmaceutical company. The Company is engaged in developing therapies for the treatment of cancer and inflammatory diseases. The Company uses its technology to create small molecule drug conjugates (SMDCs) and companion imaging diagnostics. The Company's pipeline includes Folate-Tubulysin... (more)

Overall

Beta: 0.40
Market Cap(Mil.): $1,188.48
Shares Outstanding(Mil.): 69.50
Dividend: --
Yield (%): --

Financials

  ECYT.OQ Industry Sector
P/E (TTM): -- 217.69 33.34
EPS (TTM): -1.16 -- --
ROI: -34.84 -3.65 13.18
ROE: -34.97 -5.62 15.09

BRIEF-Endocyte Reports Q1 Loss Per Share $0.16

* Q1 EARNINGS PER SHARE VIEW $-0.19 -- THOMSON REUTERS I/B/E/S

May 09 2018

BRIEF-Endocyte Says Data Presented At AACR Show That EC17 Penetrates Solid Tumors Within Minutes And Is Retained Due To High Affinity For Folate Receptor

* ENDOCYTE INC - DATA PRESENTED AT AACR SHOW THAT EC17 PENETRATES SOLID TUMORS WITHIN MINUTES AND IS RETAINED DUE TO HIGH AFFINITY FOR FOLATE RECEPTOR Source text for Eikon: Further company coverage:

Apr 16 2018

BRIEF-Endocyte Nominates Dawn Svoronos For Election To Its Board

* ENDOCYTE NOMINATES DAWN SVORONOS FOR ELECTION TO ITS BOARD OF DIRECTORS AND ANNOUNCES OTHER BOARD DEVELOPMENTS

Mar 15 2018

BRIEF-Endocyte Says ‍In Connection With Machado's Election, Board Increased Size To 11 Members​

* ENDOCYTE INC SAYS ‍IN CONNECTION WITH MACHADO'S ELECTION, BOARD INCREASED SIZE OF BOARD FROM 10 TO 11 MEMBERS - SEC FILING​ Source text: (http://bit.ly/2FKviW0) Further company coverage:

Mar 02 2018

BRIEF-Endocyte Announces Proposed Public Offering Of Common Stock

* ENDOCYTE ANNOUNCES PROPOSED PUBLIC OFFERING OF COMMON STOCK

Feb 27 2018

BRIEF-Endocyte Inc Appoints Patrick Machado To Its Board

* ENDOCYTE APPOINTS PATRICK MACHADO, J.D. TO ITS BOARD OF DIRECTORS Source text for Eikon: Further company coverage:

Feb 27 2018

BRIEF-Endocyte Announces Phase 3 Vision Trial,Provides Update On Corporate Strategy And Reports Q4 And 2017 Financial Results

* ENDOCYTE ANNOUNCES PHASE 3 VISION TRIAL AND PROVIDES UPDATE ON CORPORATE STRATEGY AND REPORTS FOURTH QUARTER AND YEAR END 2017 FINANCIAL RESULTS

Feb 26 2018

BRIEF-Endocyte And ITM Announce Supply Agreement

* ENDOCYTE AND ITM ANNOUNCE SUPPLY AGREEMENT FOR NO-CARRIER-ADDED LUTETIUM FOR THE PHASE 3 VISION TRIAL

Feb 26 2018

Competitors

Earnings vs. Estimates